Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FDPS | P14324 | 19/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31168022 | 1.00 | MEN1 (0.57) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL31167993 | 0.96 | MEN1 (0.56) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL14644851 | 0.94 | MEN1 (0.53) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL23117618 | 0.94 | MEN1 (0.49) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL34146 | 0.93 | MEN1 (0.51) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL13161377 | 0.92 | MEN1 (0.49) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| Trifluoromethanesulfonic Acid SCHEMBL1976895 | 0.91 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL34147 | 0.90 | MEN1 (0.48) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL34726 | 0.89 | FDPS (0.46) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS | |
| SCHEMBL10231654 | 0.88 | MEN1 (0.40) | MEN1HSP90AA1KMT2ASMN1; SMN2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | MEN1 4785/4885HSP90AA1 2326/4885KMT2A 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.